The blast phase of chronic myeloid leukaemia

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 3, 2009, Pages 387-394

  Silver, Richard T ^a  

^a Department of Medicine   (United States)

Author keywords

chemotherapy of blast phase; chronic myeloid leukaemia, blast phase; historical perspective, pathogenesis and treatment of chronic myeloid leukaemia blast phase

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMSACRINE; AZACITIDINE; AZASERINE; BCR ABL PROTEIN; CARBOPLATIN; CYTARABINE; DASATINIB; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; MERCAPTOPURINE; MITHRAMYCIN; MITOXANTRONE; NILOTINIB; PREDNISONE; TIOGUANINE; TROXACITABINE; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AMINO ACID SUBSTITUTION; BLAST CELL CRISIS; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FLUID RETENTION; GENE MUTATION; HEART ARRHYTHMIA; HUMAN; LEUKEMIA REMISSION; NEUTROPENIA; OVERALL SURVIVAL; PATHOGENESIS; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QT INTERVAL; REVIEW; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA;

BONE MARROW TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; PROGNOSIS; PROTEIN KINASE INHIBITORS; REMISSION INDUCTION;

EID: 71849083260     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.07.006     Document Type: Review

References (45)

1. Karanas A., and Silver R.T. Characteristics of the terminal phase of chronic granulocytic leukemia. Blood 32 (1968) 445
2. Kantarjian H., O'Brien S., Cortes J., et al. Sudden onset of the blastic phase of chronic myelogeneous leukemia: patterns and implications. Cancer 98 (2003) 81-85
3. Jabbour E., Kantarjian H., O'Brien S., et al. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107 (2006) 480-482
4. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 (2003) 1423-1432
5. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytologic responses in patients with chronic myelogeneous leukemia in myeloid blast crisis: results of a phase II study. Blood 99 (2002) 3530-3539
6. Vardiman J.W., Harris N.L., and Bruning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
7. Cortes J.E., O'Brien S., Garcia-Manero G., et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 104 (2004) 1979-1988
8. Quintas-Cardama A., and Cortes J. Molecular biology of bcr-abl 1-Positive chronic myeloid leukemia. Blood 113 (2009) 1619-1630
9. Cortes J., Silver R.T., and Kantarjian H. Chronic myeloid leukemia in Holland-Frei. Medicine. Cancer 7 (2006) 1761-1771 edited by Kufe DW, Bast RC, Hait WN, et al., BC Decker, Inc., Hamilton, London
10. Takahashi N., Miura I., Saito H.K., et al. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting progressives in situ hybridization. Blood 92 (1998) 4758-4763
11. Bain B., Catovsky D., O'Brien M., et al. Megakaryoblastic transformation of chronic granulocytic leukemia. An electron microscopy and cytochemical study. J Clin Pathol 30 (1977) 235-242
12. Rosenthal S., Cancellos G.P., and Gralnick H.P. Erythroblastic transformation of chronic granulocytic leukemia. Am J Med 63 (1977) 116-124
13. Mughal T., Cortes J., Cross N.C., et al. Chronic myeloid leukemia-some topical issues. Leukemia 7 (2007) 1347-1352
14. Feinstein E., Cimino G., Gale R.P., et al. P53 in chronic myelogeneous leukemia in acute phase. Proc Natl Acad Sci U S A 88 (1991) 6293-6297
15. Sill H., Goldman J.M., and Cross N.C. Homozygous deletions of the P16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85 (1995) 2013-2016
16. Cross N.C.P., Daley G.Q., Green A.R., et al. BCR-ABL 1-positive CML and BCR-ABL 1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia 22 (2008) 1975-1989
17. Mughal T.I., and Goldman J.L. Chronic myeloid leukemia: Why does it evolve from chronic phase to blastic transformation?. Front Biosci 11 (2006) 198-278
18. Jamieson C.H., Ailles L.E., Dylla S.J., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351 (2004) 657-667
19. Hehlmann R., and Saussele S. Treatment of chronic myeloid leukemia in blast crisis. Haematologica 93 (2008) 1765-1769
20. Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 103 (2006) 2794
21. Zheng C., Li L., Haak M., et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 20 (2006) 1028-1034
22. Hayes D.M., Ellison R.R., Glidwell O., et al. Chemotherapy for the terminal phase of chronic myelocytic leukemia. Cancer Chemotherapy Rep Part 2 4 (1974) 233-247
23. Coleman M., Silver R.T., Pajak T.F., et al. Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. Blood 55 (1980) 29-36
24. Dutcher J.P. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogeneous leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia 6 (1992) 770-775
25. Kantarjian H., O'Brien S., Cortes J., et al. Results of decitabine (5-aza-2′ deoxycytidine) therapy in 130 patients with chronic myelogeneous leukemia. Cancer 98 (2003) 522-528
26. Dutcher J.P., Lee S., Paietta E., et al. Phase II study of carboplatinin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group study E1992. Leukemia 12 (1998) 1037-1040
27. Feldman E.J., Alberts D.S., Arlin Z., et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 11 (1993) 2002-2009
28. Giles F.J., Garcia-Manero G., Cortes J.E., et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog in patients with refractory leukemia. J Clin Oncol 20 (2002) 656-664
29. O'Brien S., Kantarjian H., Keating M., et al. Homoharringtonine therapy induces responses in patients with chronic myelogeneous leukemia in late chronic phase. Blood 86 (1995) 3322-3326
30. Bauduer F., Delmer A., Blanc M., et al. Treatment of chronic myelogeneous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine. Leuk Lymphoma 10 (1993) 195-200
31. Koller C.A., and Miller D.M. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med 315 (1986) pp. 1433-1438
32. Thomas E.D., Cliff R.A., Fefer A., et al. Marrow transplantation for the treatment of chronic myelogeneous leukemia. Ann Intern Med 104 (1986) 155-163
33. Gratwohl A., and Hermans J. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 3 (1996) S7-S9
34. Silver R.T., Talpaz M., Sawyers C.L., et al. Four years of follow-up of 1027 patients with late chronic phase (LCP), accelerated phase (AP), or blast crisis (BC), chronic myeloid leukemia (CML) treated with imatinib in three large Phase II trials. Blood 104 (2004) 123
35. Palandri F., Castagnetti F., Testoni N., et al. Chronic myeloid leukemia in blast crisis treated with Imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up. Haematologica 93 (2008) 1792-1796
36. Silver R.T., Cortes J., Waltzman R., et al. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica 94 (2009) 743-744
37. O'Hare T., Walters D.K., Stoffregen E.P., et al. In Vitro activity of Bcr-Abl inhibitors AMN107 & BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005) 4500-4505
38. Shah N.P., Tran C., Lee F.Y., et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
39. Cortes J., Jabbour E., Kantarjian H., et al. The dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 7 (2007) 4005-4011
40. Giles F., le Coutre P., Bhalla K., et al. A phase II study of nilotinib administered to patients with imatinib resistance or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 18S (2007) 7038 [abstract]
41. Kantarjian H., Giles F., Gutterman N., et al. Nilotinib (formerly AMN107) A highly selective BCR-ABL tyrosine kinase inhibitor is effective in patients with Philadelphia chromosome-positive chronic myelogeneous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110 (2007) 3540-3546
42. Goldman J.M. How I treat chronic myeloid leukemia in the imatinib era. Blood 110 (2007) 2828-2837
43. Silver R.T., Woolf S.H., Hehlmann R., et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94 (1999 Sep 1) 1517-1536
44. Atallah E., Kantarjian H., deLima M., et al. The role of dasatinib in patients with Philadelphia positive acute lymphocytic leukemia (ALL) and chronic myeloid leukema (CML) relapsing after stem cell transplantation (SCT). Blood 108 (2006) [abstract 4120]
45. Quintas-Cardama A., and Cortes J. Kinase inhibitors in chronic myelogeneous leukemia. Clin Adv Hematol Oncol 4 (2006) 365-373